Aethlon Medical Inc(AEMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -40.99 | Insider Own | 0.76% | Shs Outstand | 1.6M | Perf Week | -4.84% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 70.59% | Insider Trans | - | Shs Float | 1.6M | Perf Month | -15.98% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -2.7 | Inst Own | 5.97% | Short Float | 4.75% | Perf Quarter | 79.33% |
| Income | -0.01B | P/S | - | EPS this Y | 87.76% | Inst Trans | 3.81% | Short Ratio | 0.03 | Perf Half Y | -54.81% |
| Sales | 0.00B | P/B | 0.49 | EPS next 5Y | 76.48% | ROA | -120.22% | Short Interest | 0.08M | Perf YTD | -61.66% |
| Book/sh | 10.89 | P/C | 1.73 | EPS past 3/5Y | 71.71% 54.12% | ROE | -160.91% | 52W High | -81.97% ($29.45) | Perf Year | -80.73% |
| Cash/sh | 3.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -133.43% | 52W Low | 276.6% ($1.41) | Perf 3Y | -99.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 87.54% | Gross Margin | - | Volatility(W/M) | 8.06% 6.63% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.46 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 5.04 | EPS Q/Q | 90.52% | Profit Margin | - | RSI (14) | 51.23 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | - | SMA20 | -11.75% ($6.02) | Beta | 1.26 | Target Price | $13.25 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/8/13 | SMA50 | 29.63% ($4.1) | Rel Volume | 0.01 | Prev Close | $5.16 |
| Employees | 9 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.42% - | SMA200 | -34.33% ($8.09) | Avg Volume(3M) | 2.53M | Price | $5.31 |
| IPO | 1994/5/11 | Option/Short | No/Yes | Trades | 354 | Volume | 36,488 | Change | 2.91% |
🩸 (Aethlon Medical) is a clinical-stage medical device company headquartered in San Diego, California, USA. Through its proprietary blood purification device, the Hemopurifier®, the company holds technology that removes tumor-derived extracellular vesicles (EVs) and enveloped viruses from the blood, and is currently conducting a clinical trial in Australia targeting patients with solid tumors who are unresponsive to immuno-oncology drugs.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
AEMD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +87.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.0%.
Tap to view numbers
It ranks #121 of 142 in the industry
Based on market cap of $9M.
PLSM#119 Pulsenmore Ltd $11M PER - 
NMTC#120 NeuroOne Medical Technologies Corp $9M PER - AEMD#121 Aethlon Medical Inc $9M PER - 
BMRA#122 Biomerica Inc $8M PER - 
TNON#123 Tenon Medical Inc $7M PER - 
FAQ
What kind of company is AEMD?
AEMD belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of AEMD?
The market cap of AEMD is approximately $9M, ranking 5,480 within its sector.
What is the 52-week high and low for AEMD?
AEMD has recorded a 52-week high of $29.45 and a low of $1.41.
